Antibiotic treatment targets difficult asthmaDecember 18, 2007Hunter researchers have shown that a commonly available antibiotic can improve the quality of life of patients with difficult asthma, and may also generate significant health care savings. Results of a study published in the American Journal of Respiratory and Critical Care Medicine, a top international journal, indicate that macrolide antibiotics could prove a successful therapy in conjunction with current asthma treatment. The study was conducted by researchers from the University of Newcastle and Hunter New England Health in collaboration with the Hunter Medical Research Institute (HMRI) Viruses, Infections/Immunity,Vaccines and Asthma (VIVA) Research Program. Current asthma medication is focused on treating a particular cell, called an eosinophil. Increased levels of eosinophils are thought to be responsible for inflammation of the airways. However, almost half of people with asthma symptoms have normal levels of eosinophils. "In a previous study we have shown that an inflammatory cell called the neutrophil is increased in some asthma patients and that treatments are needed to combat other types of inflammation in people with asthma," said Dr Jodie Simpson from the University of Newcastle's Priority Research Centre for Asthma and Respiratory Diseases. Researchers studied 45 people who had poor asthma control and were taking high daily maintenance doses of inhaled corticosteroids. In addition to their regular asthma therapy, participants received a macrolide antibiotic (called klacid) or placebo medication for eight weeks. "In this study we have shown that treatment with a macrolide antibiotic for eight weeks significantly reduced inflammation in the airways and improved quality of life in patients with difficult asthma," said Dr Simpson. "Patients with non-eosinophilic asthma particularly benefited from this treatment and this group of patients had the biggest response to the treatment. This treatment significantly reduced the number of neutrophils in the airway. "This finding is significant because 5 to 10 per cent of asthma cases are considered difficult and these account for 50 per cent of asthma treatment and health care costs." Research Australia |
|||||||||||||||||||||
| Related Asthma Current Events and Asthma News Articles Exposures to metals and diesel emissions in air linked to respiratory symptoms in children Exposure shortly after birth to ambient metals from residential heating oil combustion and particles from diesel emissions are associated with respiratory symptoms in young inner city children. Exposure to both traffic, indoor pollutants puts some kids at higher risk for asthma later New research presents strong evidence that the "synergistic" effect of early-life exposure to both outdoor traffic-related pollution and indoor endotoxin causes more harm to developing lungs than one or the other exposure alone. Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps A protein known to stimulate blood vessel growth has now been found to be responsible for the cell overgrowth in the development of polyps that characterize one of the most severe forms of sinusitis, a study by Johns Hopkins researchers suggests. Ancestry attracts, but love is blind People preferentially marry those with similar ancestry, but their decisions are not necessarily based on hair, eye or skin colour. Common plastics chemicals linked to ADHD symptoms Phthalates are important components of many consumer products, including toys, cleaning materials, plastics, and personal care items. Asthma a significant risk factor for complications in children with H1N1 A new study on pediatric H1N1 influenza admissions has found that asthma is a significant risk factor for severe disease in children with pandemic H1N1 compared with the seasonal flu. Mother's Depression a Risk Factor in Childhood Asthma Symptoms, Study Suggests Asthma symptoms can worsen in children with depressed mothers, according to research from Johns Hopkins Children's Center published online in the Journal of Pediatric Psychology. Sweet -- sugared polymer a new weapon against allergies and asthma Scientists at Johns Hopkins and their colleagues have developed sugar-coated polymer strands that selectively kill off cells involved in triggering aggressive allergy and asthma attacks. Pivotal study for PSD502 -- the first potential treatment for premature ejaculation At the annual meeting of the Sexual Medicine Society of North America (SMSNA), Inc. in San Diego, Sciele Pharma, Inc., a Shionogi Company and Plethora Solutions Limited, a wholly owned subsidiary of Plethora Solutions Holdings PLC ("Plethora" - AIM:PLE)., today presented data from its second positive pivotal study of PSD502 for the treatment of premature ejaculation (PE). Aileron collaborates study in Nature: Stapled peptides inhibit Notch1 transcription factor This research validates the potential for Stapled Peptides to modulate key intracellular biological targets, such as transcription factors, that have not been addressable with current small molecule or biologic drug modalities. More Asthma Current Events and Asthma News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||